Biomarkers in lung cancer: From early detection to novel therapeutics and decision making

Biomarkers in Medicine

Volumn 2, Issue 6, 2008, Pages 577-586

  Scott, April ^a   Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Biomarkers; Lung cancer; Predictive markers; Prognostic markers

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ALPHA 1 ANTITRYPSIN; ANTINEOPLASTIC AGENT; BIBW 2992; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CELECOXIB; CETUXIMAB; CHROMOGRANIN A; CISPLATIN; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; LACTATE DEHYDROGENASE; MYC PROTEIN; NAVELBINE; NEURON SPECIFIC ENOLASE; PANITUMUMAB; PLATINUM COMPLEX; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETINOL BINDING PROTEIN; SCATTER FACTOR RECEPTOR; SQUAMOUS CELL CARCINOMA ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 647;

AGE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE MARKER; DNA REPAIR; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; EARLY DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; MASS SPECTROMETRY; MEDICAL DECISION MAKING; NONHUMAN; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 59949099451     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.6.577     Document Type: Review

References (88)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Muley T, Dienemann H, Ebert W: Increased CYFRA 21-21 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res. 23(5b), 4085-4093 (2003).
3. Sakao Y, Tomimitsu S, Takeda Y, Natsuaki M, Itoh T: Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. Eur. J. Cardiothorac. Surg. 25(4), 520-522 (2004).
4. Salgia R, Harpole D, Herndon JE 2nd, Pisick E, Elias A, Skarin AT: Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res. 21(2B), 1241-1246 (2001).
5. Lassen U, Osterlind K, Hansen M, Dombernowskv P, Bergman B, Hansen HH: Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years: an analysis of 1,714 consecutive patients. J. Clin. Oncol. 13(5), 1215-1220 (1995).
6. Byhardt RW, Hartz A, Libnoch JA, Hansen R, Cox JD: Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int. J. Radiat. Oncol. Biol. Phys. 12(5), 771-777 (1986).
7. Jaques G, Bepler G, Holle R et al.: Prognostic value of pretreatment carcinoembryonic antigen, neuron-specific enolase, and creatine kinase-BB levels in sera of patients with small cell lung cancer. Cancer 62(1), 125-134 (1988).
8. Johnson PW, Joel SP, Lave S et al.: Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br. J. Cancer 67(4), 760-766 (1993).
9. Fizazi K, Cojean I, Pignon JP et al.: Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 82(6), 1049-1055 (1998).
10. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd: Panel of serum biomarkers for the diagnosis of lung cancer. J. Clin. Oncol. 25(35), 5578-5583 (2007).
11. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade ofprogress. Chest 122(3), 1037-1057 (2002).
12. McCarthy NJ, Swain SM: Tumor markers: should we or shouldn't we? Cancer J. 7(3), 175-177 (2001).
13. Hirano T, Franzén B, Uryu K et al.: Detection of polypeptides associated with the histopathological differentiation of primary lung carcinoma. By. J. Cancer 72(4), 840-848 (1995).
14. Okuzawa K, Franzén B, Lindholm J et al.: Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 15(3-4), 382-390 (1994).
15. Anderson NL, Polanski M, Pieper R et al.: The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell Proteomics 3(4), 311-326. (2004).
16. Yanagisawa K, Shyr Y, Xu BJ et al.: Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362(9382), 433-439 (2003).
17. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ: Proteomic patterns: their potential for disease diagnosis. Mol. Cell Endocrinol. 230(1-2), 95-106 (2005).
18. Rodenhuis S, Slebos RJ: The ras oncogenes in human lung cancef. Am. Rev. Respir. Dis. 142(6 Pt 2), S27-S30 (1990).
19. Rodenhuis S, Slebos RJ, Boot AJ et al.: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 48(20), 5738-5741 (1988).
20. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL: Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317(15), 929-935 (1987).
21. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF: Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6(8), 1353-1362 (1991).
22. Slebos RJ, Kibbelaar RE, Dalesio O et al.: K-ras oncogene activation as a prognostic market in adenocarcinoma of the lung. N. Engl. J. Med. 323(9), 561-565 (1990).
23. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT: Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J. Natl Cancer Inst. 91(23), 2032-2038 (1999).
24. Riely GJ, Kris MG, Rosenbaum D et al.: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 14(18), 5731-5734 (2008).
25. Mascaux C, Iannino, N, Martin B et al.: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer 92 (1), 131-139 (2005).
26. Schiller JH, Adak S, Feins RH et al.: Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin. Oncol. 19 (2), 448-457 (2001).
27. Graziano SL, Gamble GP, Newman NB et al.: Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II'non-small-cell lung cancer. J. Clin. Oncol. 17(2), 668-675 (1999).
28. Tsao MS, Aviel-Ronen S, Ding K et al.: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol. 25 (33). 5240-5247(2007).
29. Amado RG, Wolf M, Peeters M et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
30. Pirker R, Szezesna A, von Pawel J et al.: FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26(Suppl. 20), (2008).
31. Comoglio PM: Structure, biosysnthesis and biochemical properties of the HGF receptor in normal and malignant cells. EXS 65, 131-165 (1993).
32. Comoglio PM, Boccaccio C: The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells 1(4), 347-354 (1996).
33. Di Renzo MF, Narsimhan RP, Olivero M et al.: Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6(11), 1997-2003 (1991).
34. Christensen JG, Burrows J, Salgia R: c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225 (1), 1-26 (2005).
35. Jeffers M, Fiscella M, Webb CP, Anver M, Koochckpour S, Vande Woude GF: The mutationally activated Met receptor mediates motility and metastasis. Proc. Natl Acad. Sci. USA 95(24), 14417-14422 (1998).
36. Tokunou M, Niki T, Eguchi K et al.: c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am. J. Pathol. 158 (4), 1451-1463 (2001).
37. Cheng TL, Chang MY, Huang SY et al.: Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 128 (3), 1453-1460 (2005).
38. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al.: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21(20), 3798-3807 (2003).
39. Kurie JM, Shin HJ, Lee JS et al.: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin. Cancer Res. 2(10), 1787-1793 (1996).
40. Piyathilake CJ, Frost AR, Marine U et al.: Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin. Cancer Res. 8(3), 734-744 (2002).
41. Cox G, Jones JL, O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin. Cancer Res. 6(6), 2349-2355(2000).
42. Ohsaki Y, Tanno S, Fujita Y et al.: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep. 7(3), 603-607 (2000).
43. Volm M, Rittgen W, Drings P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer 77(4), 663-669 (1998).
44. Parra HS, Cavina R, Latteri F et al.: Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br. J. Cancer 91(2), 208-212 (2004).
45. Pastorino U, Andreola S, Tagliabue E et al.: Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol. 15(8), 2858-2865 (1997).
46. Pfeiffer P, Clausen PP, Andersen K, Rose C: Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br. J. Cancer 74(1), 86-91 (1996).
47. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor a is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3(4), 515-522 (1997).
48. Gatzemeier U, Pluzanska A, Szczesna A et al.: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545-1552 (2007).
49. Herbst RS, Prager D, Hermann R et al.: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
50. Giaccone G, Herbst RS, Manegold C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004).
51. Herbst RS, Giaccone G, Schiller JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 22(5), 785-794 (2004).
52. Bezjak A, Tu D, Seymour L et al.: Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 24(24), 3831-3837 (2006).
53. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.: Erlocinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
54. Mitsudomi T, Kosaka T, Yatabe Y: Biological and clinical implications of EGFR mutations in lung cancer. Int. J. Clin. Oncol. 11 (3), 190-198 (2006).
55. Pérez-Soler R, Chachoua A, Hammond LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3238-3247 (2004).
56. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin. Cancer Res. 13(13), 3913-3921 (2007).
57. Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169-181 (2007).
58. Tsao, MS, Sakurada A, Cutz JC et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133-144 (2005).
59. Cappuzzo F, Hirsch FR, Rossi E et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97(9), 643-655 (2005).
60. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al.: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24(31), 5034-5042 (2006).
61. Ahmed SM, Salgia R: Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 11(6), 687-692 (2006).
62. Kosaka T, Yatabe Y, Endoh H et al.: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12 (19), 5764-5769 (2006).
63. Kobayashi S, Boggon TJ, Dayaram T et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786-792 (2005).
64. Engelman JA, Zejnullahu K, Mitsudomi T et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
65. Krysan K, Reckamp KL, Dalwadi H et al.: Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptorindependent manner. Cancer Res. 65(14), 6275-6281(2005).
66. Agarwala A, Fisher W, Bruetman D et al.: Gefitinib plus celecoxib in chemotherapynaive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Ontology Group. J. Thorac. Oncol. 3(4), 374-379 (2008).
67. Ji H, Zhao, X, Yuza Y et al.: Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl Acad. Sci. USA 103(20), 7817-7822 (2006).
68. Gendreau SB, Ventura R, Keast P et al.: Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin. Cancer Res. 13(12), 3713-3723 (2007).
69. Eskens FA, Mom CH, Planting AS et al.: A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer 98(1), 80-85 (2008).
70. Baryshnikova E, Destro A, Infante MV et al.: Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin. Cancer Res. 14(6), 1913-1919 (2008).
71. Tammemagi MC, McLaughlin JR, Bull SB: Meta-analyses of p53 tumor suppressor gene alterations and clinicopachological features in resected lung cancers. Cancer Epidemiol. Biomarkers Prev. 8(7), 625-634 (1999).
72. Steels E, Paesmans M, Berghmans T et al.: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur. Respir. 18(4), 705-719 (2001).
73. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res. 6(10), 4055-4063 (2000).
74. Ahrendr SA, Hu Y, Buta M et al.: p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J. Natl Cancer Inst. 95(13), 961-970 (2003).
75. Shih CM, Chen K, Wang YC, Lee PJ, Wang YC: Elevated p53 and p21waf1 mRNA expression in blood lymphocytes from lung cancer patients with chemoresistance. Cancer Detect Prev. 31(5), 366-370 (2007).
76. Salgia R, Skarin AT: Molecular abnormalities in lung cancer. J. Clin. Oncol. 16(3), 1207-1217 (1998).
77. Dosaka-Akita H, Hu SX, Fujino M et al.: Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 79(7), 1329-1337 (1997).
78. Xu HJ, Cagle PT, Hu SX, Li J, Benedict WF: Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin. Cancer Res. 2(7), 1169-1176.(1996).
79. Burke L, Flieder, DB, Guinee DG et al.: Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin. Cancer Res. 11(1), 232-241 (2005).
80. Geradts J, Fong KM, Zimmerman PV, Maynard R, Minna JD: Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin. Cancer Res. 5(4), 791-800 (1999).
81. Chen JT, Chen YC, Chen CY, Wang YC: Loss of p16 and/or pRb protein expression in NSCLC. An immunohistochemical and prognostic study. Lung Cancer 31(2-3), 163-170 (2001).
82. Zagorski WA, Knudsen ES, Reed MF: Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Res. 67(17), 8264-8273 (2007).
83. Winton T, Livingston R, Johnson D et al.: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005).
84. Neumann AS, Sturgis EM, Wei Q: Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol. Carcinog. 42(2), 65-92 (2005).
85. Bepler G, Sharma S, Cantor A et al.: RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(10), 1878-1885 (2004).
86. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 356(8), 800-808 (2007).
87. Olaussen KA, Dunant A, Fouret P et al.: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006).
88. Cobo M, Isla D, Massuti B et al.: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 25(19), 2747-2754 (2007).